NCT06565143 · RECRUITING

Effect of Transcranial Alternating Current Stimulation(tACS) for Early Alzheimer's Disease

This trial tests whether a non-invasive brain stimulation technique called transcranial alternating current stimulation, or tACS, can help people in the early stages of Alzheimer's disease. A device delivers mild electrical currents to the scalp to try to influence brain rhythms. Researchers are also using EEG to track what happens in the brain. This is a Phase N/A trial, meaning it is exploratory — not yet proven or approved.

You may qualify if

  • Subject diagnosed with early Alzheimer's disease or related diseases according to NIA-AA criteria.
  • Subjects must have a MMSE score between 10 and 27,indicating mild cognitive impairment or dementia.
  • CDR score ≤ 2.
  • Subject under treatment by IAChE for at least 3 months.
  • psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months.

You're excluded if

  • CDR > 2
  • Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder).
  • History of head injury,stroke,or other neurologic disease.
  • Organic brain defects on T1 or T2 images.
  • History of seizures or unexplained loss of consciousness.
  • Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator.
  • Family history of medication refractory epilepsy.
  • History of substance abuse within the last 6 months.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2024-08-21

View full record on ClinicalTrials.gov

All APOE4 clinical trials